Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
04:01pm, Tuesday, 13'th May 2025
ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing inno
MacroGenics Announces Date of First Quarter 2025 Financial Results
04:30pm, Tuesday, 06'th May 2025
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-ba
MacroGenics to Participate in Upcoming Investor Conference
04:30pm, Thursday, 01'st May 2025
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-
4 Medical Product Stocks to Buy From a Challenging Industry
09:55am, Thursday, 17'th Apr 2025
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Thursday, 03'rd Apr 2025
The heavy selling pressure might have exhausted for MacroGenics (MGNX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analyst
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
08:01pm, Thursday, 20'th Mar 2025
While the top- and bottom-line numbers for MacroGenics (MGNX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics co
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
07:51pm, Thursday, 20'th Mar 2025
MacroGenics (MGNX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.75 per share a year ago.
MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript
07:09pm, Thursday, 20'th Mar 2025
MacroGenics, Inc. (NASDAQ:MGNX ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants James Karrels - SVP, CFO and Secretary Scott Koenig - President and CEO Stephen Eck - S
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
07:30am, Thursday, 06'th Mar 2025
ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-
MacroGenics: Stacking Up A Lot Of Headwinds
02:08pm, Thursday, 27'th Feb 2025
MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale
MacroGenics to Participate in Upcoming Investor Conferences
07:30am, Thursday, 27'th Feb 2025
ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Macrogenics, Inc. (NASDAQ: MGNX)
MacroGenics to Participate in Upcoming Investor Conference
04:30pm, Monday, 02'nd Dec 2024
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoc
MacroGenics to Participate in Upcoming Investor Conferences
04:30pm, Wednesday, 06'th Nov 2024
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-b
Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings
09:00pm, Tuesday, 05'th Nov 2024
The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street
